Hospital
The Aroostook Medical Center
The Aroostook Medical Center was paid $38.59M by Medicaid between Jan 2018 and Dec 2024, across 484 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 32% of everything it billed.
33Billing provider infoTHE AROOSTOOK MEDICAL CENTER
PRESQUE ISLE, ME 04769
PRESQUE ISLE, ME 04769
33aNPI1396858999assigned 08/16/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$38.59M
24GClaims1,282,089
24DCodes billed484
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Maine
Rank by total paid#6 of 33
Median peer was paid$4.34M
This provider vs. median8.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 148,505 | $3.86M | |
| 2019 | 167,964 | $4.50M | |
| 2020 | 163,391 | $4.36M | |
| 2021 | 217,060 | $6.02M | |
| 2022 | 207,526 | $6.34M | |
| 2023 | 200,157 | $6.64M | |
| 2024incomplete | 177,486 | $6.87M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 32% | 210,468 | 157,280 | $12.25M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.7% | 10,911 | 9,667 | $2.96M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 6.5% | 65,270 | 61,142 | $2.49M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 4.9% | 13,300 | 12,103 | $1.87M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 4.6% | 65,971 | 62,621 | $1.79M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 3.6% | 11,588 | 10,540 | $1.39M |
| A0425 | Ground mileage, per statute mile | 3.5% | 4,467 | 3,638 | $1.33M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 1.8% | 12,800 | 11,220 | $705K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.8% | 7,835 | 6,818 | $700K |
| J0178 | Injection, aflibercept, 1 mg | 1.6% | 1,692 | 1,544 | $634K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.6% | 7,758 | 7,212 | $629K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.3% | 14,326 | 4,993 | $499K |
472 more codes
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.1% | 5,489 | $438K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.1% | 11,990 | $428K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 1.1% | 12,336 | $407K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 1.0% | 6,532 | $396K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 14,312 | $344K |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 6,654 | $326K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 3,195 | $316K |
| 20610 | <1% | 4,153 | $310K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 4,799 | $301K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 4,391 | $272K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 6,269 | $258K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 12,868 | $256K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 8,547 | $254K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 818 | $217K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 11,218 | $213K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 7,545 | $204K |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 17,096 | $198K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 2,834 | $198K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 1,344 | $183K |
| 71045 | Radiologic examination, chest; single view | <1% | 12,400 | $182K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 3,034 | $173K |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | <1% | 1,209 | $171K |
| 97533 | <1% | 4,069 | $166K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 6,364 | $160K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 2,827 | $155K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 608 | $152K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 9,995 | $141K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,425 | $137K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,956 | $127K |
| J0897 | Injection, denosumab, 1 mg | <1% | 136 | $111K |
| A0429 | Emergency ambulance ride, basic life support | <1% | 970 | $108K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 2,914 | $104K |
| A0434 | Specialty care transport (sct) | <1% | 292 | $99K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 9,199 | $98K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 1,643 | $95K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 1,635 | $89K |
| A0427 | Emergency ambulance ride, advanced life support | <1% | 882 | $87K |
| 92557 | <1% | 3,979 | $82K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 6,286 | $78K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,013 | $74K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,154 | $72K |
| G0451 | Development testing, with interpretation and report, per standardized instrument form | <1% | 1,195 | $70K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 8,719 | $69K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 1,460 | $69K |
| G0008 | Administration of influenza virus vaccine | <1% | 4,034 | $67K |
| 80061 | Lipid panel | <1% | 9,514 | $66K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 2,556 | $66K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,764 | $63K |
| 94060 | <1% | 959 | $61K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 136 | $60K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 16,737 | $59K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 929 | $55K |
| 80053 | Comprehensive metabolic panel | <1% | 37,720 | $54K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 12,014 | $52K |
| 97161 | <1% | 1,818 | $52K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 396 | $51K |
| 86900 | <1% | 1,787 | $50K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 703 | $48K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 2,358 | $45K |
| Q3014 | Telehealth originating site facility fee | <1% | 3,445 | $42K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 42,466 | $41K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 630 | $40K |
| 92134 | <1% | 12,456 | $40K | |
| 76830 | Ultrasound, transvaginal | <1% | 581 | $40K |
| 0001A | <1% | 2,283 | $39K | |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 558 | $39K |
| 0002A | <1% | 2,082 | $39K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 357 | $38K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 780 | $36K |
| 97165 | <1% | 984 | $34K | |
| 90836 | <1% | 1,880 | $33K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,285 | $32K |
| 95811 | <1% | 458 | $31K | |
| 92523 | <1% | 344 | $30K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,324 | $30K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 659 | $29K |
| 98926 | <1% | 2,000 | $29K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 434 | $28K |
| 11721 | <1% | 4,689 | $28K | |
| 98927 | <1% | 2,026 | $28K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,995 | $27K |
| 71250 | <1% | 1,028 | $27K | |
| 94726 | <1% | 1,441 | $27K | |
| 71271 | <1% | 833 | $26K | |
| 78451 | <1% | 64 | $26K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 325 | $26K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,361 | $25K |
| 93017 | <1% | 1,036 | $23K | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 1,046 | $23K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 98 | $23K |
| 90686 | <1% | 3,649 | $23K | |
| 17110 | <1% | 698 | $22K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 293 | $21K |
| 96161 | <1% | 939 | $21K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 34,256 | $20K |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 474 | $20K |
| 90473 | <1% | 681 | $19K | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 52 | $18K |
| 11057 | <1% | 480 | $18K | |
| 99223 | Prolong inpt eval add15 m | <1% | 335 | $17K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 635 | $17K |
| 95165 | Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials | <1% | 799 | $17K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 11,283 | $17K |
| 73630 | <1% | 4,420 | $17K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 238 | $16K |
| 74018 | <1% | 2,282 | $16K | |
| 99308 | Subsequent nursing facility care, per day, straightforward | <1% | 1,048 | $15K |
| 73030 | <1% | 3,593 | $15K | |
| 62323 | <1% | 66 | $15K | |
| 95806 | <1% | 377 | $14K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,085 | $14K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 941 | $13K |
| 82607 | <1% | 3,869 | $13K | |
| 31575 | <1% | 205 | $13K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 187 | $12K |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 501 | $12K |
| 92567 | <1% | 4,516 | $12K | |
| 73502 | <1% | 2,660 | $12K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 56 | $12K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 10,270 | $12K |
| 73562 | <1% | 3,227 | $11K | |
| 82728 | <1% | 4,096 | $11K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 15,186 | $11K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 199 | $11K |
| 90677 | <1% | 669 | $10K | |
| 96415 | <1% | 336 | $10K | |
| 73610 | <1% | 2,478 | $10K | |
| 72100 | <1% | 725 | $10K | |
| 99443 | <1% | 319 | $10K | |
| 95117 | <1% | 2,764 | $10K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 40 | $10K |
| 92588 | <1% | 97 | $10K | |
| 96127 | <1% | 1,089 | $10K | |
| 64493 | <1% | 18 | $10K | |
| 84702 | <1% | 1,114 | $9K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 880 | $9K |
| D1206 | Topical application of fluoride varnish | <1% | 876 | $9K |
| 73130 | <1% | 1,736 | $9K | |
| 82962 | <1% | 22,775 | $9K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 28 | $9K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 458 | $9K |
| 73110 | <1% | 2,104 | $8K | |
| 93247 | <1% | 184 | $8K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,691 | $8K |
| 99490 | Ccm add 20min | <1% | 417 | $8K |
| 93971 | <1% | 260 | $8K | |
| 95024 | <1% | 281 | $7K | |
| 84439 | <1% | 2,519 | $7K | |
| 99188 | <1% | 284 | $7K | |
| 90480 | <1% | 526 | $7K | |
| 31231 | <1% | 83 | $7K | |
| 93225 | <1% | 303 | $6K | |
| 0004A | <1% | 429 | $6K | |
| 83550 | <1% | 3,620 | $6K | |
| 72141 | <1% | 64 | $6K | |
| 52000 | <1% | 43 | $6K | |
| 90651 | <1% | 1,006 | $6K | |
| 83735 | <1% | 7,482 | $6K | |
| 0071A | <1% | 266 | $6K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 7,532 | $6K |
| 77080 | <1% | 445 | $5K | |
| 73221 | <1% | 55 | $5K | |
| 85027 | <1% | 3,715 | $5K | |
| 91322 | <1% | 130 | $5K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 26 | $5K |
| 82746 | <1% | 1,774 | $5K | |
| 97162 | <1% | 202 | $5K | |
| 90732 | <1% | 112 | $5K | |
| 83540 | <1% | 3,853 | $5K | |
| C9257 | Injection, bevacizumab, 0.25 mg | <1% | 1,858 | $5K |
| 97116 | <1% | 420 | $5K | |
| 88142 | <1% | 631 | $5K | |
| 99307 | <1% | 561 | $5K | |
| 0072A | <1% | 227 | $4K | |
| G0127 | Trimming of dystrophic nails, any number | <1% | 660 | $4K |
| 69210 | <1% | 774 | $4K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 546 | $4K |
| 85610 | <1% | 6,735 | $4K | |
| 86140 | <1% | 4,520 | $4K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 194 | $4K |
| 20611 | <1% | 38 | $4K | |
| 99309 | Subsequent nursing facility care, per day, low to moderate complexity | <1% | 244 | $4K |
| 76536 | <1% | 79 | $3K | |
| 11056 | <1% | 1,053 | $3K | |
| 86803 | <1% | 1,032 | $3K | |
| 73564 | <1% | 350 | $3K | |
| 84153 | <1% | 1,020 | $3K | |
| G0260 | Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography | <1% | 14 | $3K |
| 77336 | <1% | 102 | $3K | |
| 87390 | <1% | 646 | $3K | |
| 70486 | <1% | 68 | $3K | |
| 99406 | <1% | 229 | $3K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 211 | $3K |
| 90656 | <1% | 361 | $3K | |
| 90670 | <1% | 1,776 | $3K | |
| 87081 | <1% | 2,224 | $3K | |
| 83880 | <1% | 2,002 | $3K | |
| 86038 | <1% | 807 | $3K | |
| 11720 | <1% | 1,733 | $3K | |
| 90838 | <1% | 271 | $3K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,084 | $2K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,087 | $2K |
| 0124A | <1% | 290 | $2K | |
| G0433 | Infectious agent antibody detection by enzyme-linked immunosorbent assay (elisa) technique, hiv-1 and/or hiv-2, screening | <1% | 277 | $2K |
| 64483 | <1% | 13 | $2K | |
| 97035 | <1% | 410 | $2K | |
| 83655 | <1% | 1,099 | $2K | |
| 91320 | <1% | 233 | $2K | |
| 0054A | <1% | 143 | $2K | |
| 99205 | Prolong outpt/office vis | <1% | 44 | $2K |
| G0009 | Administration of pneumococcal vaccine | <1% | 346 | $2K |
| 85652 | <1% | 4,580 | $2K | |
| 92083 | <1% | 979 | $2K | |
| 11102 | <1% | 40 | $2K | |
| 98928 | <1% | 150 | $2K | |
| 81025 | <1% | 3,997 | $2K | |
| 87077 | <1% | 4,831 | $2K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 43 | $2K |
| 77427 | <1% | 63 | $2K | |
| 90620 | <1% | 333 | $2K | |
| 93880 | <1% | 58 | $2K | |
| 94729 | <1% | 1,414 | $2K | |
| 94010 | <1% | 104 | $2K | |
| 87340 | <1% | 965 | $2K | |
| 80305 | <1% | 3,901 | $2K | |
| 97597 | <1% | 41 | $2K | |
| 86702 | <1% | 651 | $2K | |
| 93016 | <1% | 213 | $2K | |
| A0426 | Ambulance service, advanced life support, non-emergency transport, level 1 (als 1) | <1% | 16 | $2K |
| 86592 | <1% | 500 | $2K | |
| 87186 | <1% | 3,106 | $2K | |
| 92015 | Determination of refractive state | <1% | 2,371 | $2K |
| 87070 | <1% | 5,158 | $2K | |
| 93018 | <1% | 261 | $2K | |
| 82043 | <1% | 2,358 | $2K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 152 | $1K |
| 73560 | <1% | 345 | $1K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 106 | $1K |
| 86701 | <1% | 651 | $1K | |
| 76642 | <1% | 25 | $1K | |
| 58300 | <1% | 26 | $1K | |
| 93243 | <1% | 24 | $1K | |
| 97163 | <1% | 40 | $1K | |
| 87205 | <1% | 3,183 | $1K | |
| 84703 | <1% | 2,095 | $1K | |
| 99220 | <1% | 27 | $1K | |
| 82784 | <1% | 538 | $1K | |
| 90662 | <1% | 1,105 | $1K | |
| 93227 | <1% | 108 | $1K | |
| 72110 | <1% | 157 | $1K | |
| 90682 | <1% | 44 | $1K | |
| 80076 | <1% | 465 | $1K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,837 | $1K |
| 86706 | <1% | 249 | $1K | |
| 99496 | <1% | 27 | $1K | |
| 81001 | <1% | 6,153 | $977.56 | |
| 82533 | <1% | 176 | $955.37 | |
| 83970 | <1% | 125 | $885.50 | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 13 | $882.64 |
| 93248 | <1% | 123 | $880.39 | |
| 83690 | <1% | 4,778 | $879.92 | |
| 83615 | <1% | 1,245 | $869.55 | |
| 84403 | <1% | 69 | $851.13 | |
| 81003 | <1% | 7,497 | $844.71 | |
| 82105 | <1% | 82 | $820.96 | |
| 82570 | <1% | 890 | $810.93 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,703 | $784.53 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 4,206 | $763.68 |
| 82565 | <1% | 680 | $697.56 | |
| 96376 | <1% | 2,969 | $675.47 | |
| 99442 | <1% | 57 | $656.75 | |
| 86850 | <1% | 1,721 | $643.57 | |
| 90715 | <1% | 2,856 | $640.44 | |
| 97018 | <1% | 323 | $630.29 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,697 | $604.98 |
| 84100 | <1% | 769 | $602.69 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,703 | $599.82 |
| 11719 | <1% | 1,017 | $590.94 | |
| 69209 | <1% | 195 | $538.44 | |
| 85730 | <1% | 815 | $538.01 | |
| 97166 | <1% | 13 | $528.18 | |
| 72050 | <1% | 12 | $524.07 | |
| 0064A | <1% | 42 | $513.25 | |
| 0083A | <1% | 27 | $511.98 | |
| 87040 | <1% | 1,499 | $505.16 | |
| 82948 | <1% | 3,584 | $498.01 | |
| 85018 | <1% | 812 | $480.35 | |
| 84550 | <1% | 536 | $460.22 | |
| 0081A | <1% | 18 | $432.88 | |
| 87807 | <1% | 2,393 | $431.48 | |
| 86430 | <1% | 322 | $428.65 | |
| 73140 | <1% | 111 | $428.64 | |
| 72131 | <1% | 27 | $424.39 | |
| 86003 | <1% | 13 | $423.63 | |
| 11765 | <1% | 15 | $422.81 | |
| 0031A | <1% | 17 | $421.98 | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 12 | $417.87 |
| 82677 | <1% | 29 | $414.92 | |
| 93246 | <1% | 191 | $393.45 | |
| 81002 | <1% | 1,427 | $391.36 | |
| 17000 | <1% | 171 | $391.24 | |
| 0012A | <1% | 47 | $391.20 | |
| 73080 | <1% | 73 | $385.51 | |
| 84484 | <1% | 6,839 | $352.06 | |
| 86762 | <1% | 173 | $325.25 | |
| 0003A | <1% | 80 | $312.00 | |
| J2704 | Injection, propofol, 10 mg | <1% | 5,932 | $308.47 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,448 | $303.29 |
| 95886 | <1% | 38 | $296.68 | |
| 11055 | <1% | 54 | $294.08 | |
| 82550 | <1% | 503 | $285.77 | |
| 86336 | <1% | 29 | $279.91 | |
| 96417 | <1% | 18 | $276.56 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,720 | $256.30 |
| 0296T | <1% | 57 | $250.04 | |
| 92025 | <1% | 62 | $249.52 | |
| 86481 | <1% | 16 | $244.20 | |
| 76000 | <1% | 41 | $232.11 | |
| 84165 | <1% | 178 | $231.07 | |
| 93000 | <1% | 15 | $230.50 | |
| 96381 | <1% | 18 | $225.76 | |
| 76775 | <1% | 12 | $220.84 | |
| 74022 | <1% | 42 | $214.26 | |
| 82950 | <1% | 50 | $213.75 | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 14 | $213.03 |
| 87075 | <1% | 791 | $199.78 | |
| 90734 | <1% | 233 | $194.98 | |
| 92504 | <1% | 76 | $188.03 | |
| 83605 | <1% | 2,968 | $185.89 | |
| 82274 | <1% | 65 | $183.25 | |
| 85046 | <1% | 175 | $173.77 | |
| 83516 | <1% | 41 | $173.67 | |
| 92555 | <1% | 31 | $169.45 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 67 | $168.34 |
| 82803 | <1% | 1,074 | $166.61 | |
| 87493 | <1% | 26 | $165.87 | |
| 82077 | <1% | 2,114 | $145.60 | |
| 85379 | <1% | 1,055 | $139.83 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 425 | $137.85 |
| 92133 | <1% | 788 | $132.95 | |
| 95115 | <1% | 31 | $126.61 | |
| G0378 | Hospital observation service, per hour | <1% | 2,281 | $125.32 |
| 0298T | <1% | 26 | $124.42 | |
| 73590 | <1% | 29 | $120.52 | |
| 84156 | <1% | 88 | $116.47 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 96 | $114.48 |
| 73660 | <1% | 26 | $111.57 | |
| 82140 | <1% | 63 | $104.91 | |
| 86141 | <1% | 33 | $101.92 | |
| 84480 | <1% | 13 | $99.26 | |
| 82947 | <1% | 45 | $93.68 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 15 | $91.24 |
| 82150 | <1% | 262 | $87.17 | |
| 36591 | <1% | 17 | $83.72 | |
| 88304 | <1% | 154 | $76.75 | |
| 0011A | <1% | 29 | $71.34 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 518 | $71.17 |
| 82785 | <1% | 14 | $66.03 | |
| 86200 | <1% | 12 | $64.75 | |
| 85014 | <1% | 189 | $63.86 | |
| 93923 | <1% | 13 | $58.77 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,623 | $57.24 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,139 | $55.98 |
| 86901 | <1% | 1,824 | $52.13 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 2,073 | $48.57 |
| 84600 | <1% | 27 | $47.29 | |
| 87427 | <1% | 12 | $45.84 | |
| 93970 | <1% | 13 | $43.47 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,341 | $41.81 |
| 93280 | <1% | 14 | $41.70 | |
| 80143 | <1% | 1,598 | $41.48 | |
| 82378 | <1% | 17 | $38.15 | |
| 87046 | <1% | 12 | $37.56 | |
| 87045 | <1% | 12 | $37.56 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 2,643 | $37.23 |
| 86704 | <1% | 15 | $36.96 | |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | <1% | 26 | $33.37 |
| 80178 | <1% | 33 | $33.05 | |
| 81015 | <1% | 57 | $32.34 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,769 | $29.33 |
| 84460 | <1% | 16 | $27.46 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 2,056 | $25.95 |
| 84466 | <1% | 56 | $25.52 | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 50 | $24.13 |
| 80179 | <1% | 1,682 | $23.14 | |
| 84450 | <1% | 12 | $21.16 | |
| 86308 | <1% | 60 | $20.72 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 13 | $17.48 |
| 84132 | <1% | 17 | $14.07 | |
| 84155 | <1% | 29 | $12.77 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 66 | $12.66 |
| 84520 | <1% | 29 | $11.59 | |
| 86738 | <1% | 17 | $10.67 | |
| 82248 | <1% | 29 | $10.26 | |
| 92136 | <1% | 229 | $5.24 | |
| 17003 | <1% | 43 | $4.29 | |
| 99397 | <1% | 13 | $3.96 | |
| 90716 | <1% | 1,259 | $0.06 | |
| 90723 | <1% | 512 | $0.04 | |
| 90619 | <1% | 395 | $0.03 | |
| 90733 | <1% | 78 | $0.02 | |
| 90680 | <1% | 1,469 | $0.01 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 1,165 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 374 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 2,677 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 816 | $0.00 |
| V2632 | Posterior chamber intraocular lens | 0% | 115 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 479 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 26 | $0.00 |
| 90696 | 0% | 380 | $0.00 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 743 | $0.00 |
| 91305 | 0% | 280 | $0.00 | |
| 90697 | 0% | 705 | $0.00 | |
| 91307 | 0% | 151 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 401 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 40 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 13 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 369 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 264 | $0.00 |
| 90474 | 0% | 49 | $0.00 | |
| 99439 | 0% | 225 | $0.00 | |
| 11900 | 0% | 26 | $0.00 | |
| J2469 | Injection, palonosetron hcl, 25 mcg | 0% | 21 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 13 | $0.00 |
| 91317 | 0% | 12 | $0.00 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 0% | 233 | $0.00 |
| A9270 | Non-covered item or service | 0% | 486 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 21 | $0.00 |
| 88342 | 0% | 24 | $0.00 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 30 | $0.00 |
| 91301 | 0% | 354 | $0.00 | |
| 90381 | 0% | 37 | $0.00 | |
| C1769 | Guide wire | 0% | 28 | $0.00 |
| 90632 | 0% | 148 | $0.00 | |
| 91318 | 0% | 14 | $0.00 | |
| 51798 | 0% | 12 | $0.00 | |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 14 | $0.00 |
| 81508 | 0% | 13 | $0.00 | |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 318 | $0.00 |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | 0% | 659 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 1,483 | $0.00 |
| 87631 | 0% | 28 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 71 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 35 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 396 | $0.00 |
| 90707 | 0% | 1,240 | $0.00 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | 0% | 7,911 | $0.00 |
| 77002 | 0% | 207 | $0.00 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 52 | $0.00 |
| 93226 | 0% | 286 | $0.00 | |
| 90648 | 0% | 900 | $0.00 | |
| 90633 | 0% | 1,270 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 106 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 223 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 143 | $0.00 |
| 93325 | 0% | 13 | $0.00 | |
| 90700 | 0% | 327 | $0.00 | |
| 91308 | 0% | 137 | $0.00 | |
| 91312 | 0% | 170 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 108 | $0.00 |
| 91300 | 0% | 3,084 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 235 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 189 | $0.00 |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | 0% | 21 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 17 | $0.00 |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | 0% | 35 | $0.00 |
| 76937 | 0% | 29 | $0.00 | |
| 85380 | 0% | 12 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 12 | $0.00 |
| 87220 | 0% | 15 | $0.00 | |
| 91321 | 0% | 36 | $0.00 | |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 44 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDOBSON, SAMUEL (VP/CFO)
| Provider | Location | Paid |
|---|---|---|
| The Aroostook Medical Center | Presque Isle, ME | $526K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.